|Articles|May 24, 2022

The Latest on Monkeypox

New information suggests a few more cases have surfaced in the United States, pending CDC confirmation.


Update: Moderna tweeted the following: "Underscoring this commitment, and as #monkeypox is of global public health importance as identified by the @WHO, we are investigating potential monkeypox vaccines at a preclinical level." With this news, the company will begin work on this zoonotic virus.

Last night, the Centers for Disease Control and Prevention (CDC) said there was 1 confirmed case of monkeypox in Massachusetts, 6 cases of orthopox including the following states: 1 in New York, 1 in Washington state, 2 in Florida and 2 in Utah. The monkeypox virus is an enveloped double-stranded DNA virus that belongs to the Orthopoxvirus genus of the Poxviridae family. Outside labs can test for the orthopox virus and monkeypox diagnosis is confirmed at the CDC's facility.

First Europe, Now Here

Worldwide, the World Health Organization said there have been 200 confirmed or suspected cases of monkeypox. Mostly in non-endemic countries. Monkeypox is a viral zoonotic disease that occurs primarily in tropical rainforest areas of central and west Africa and is occasionally exported to other regions.

This most recent outbreak has been in a few countires in Europe and at least one case in the US, the aforementioned Massachusetts case, closely matches a case in Portugal, according to the CDC.

The current monkeypox circulating in Europe is reported to be mild and has a fatality rate of less than 1%. Most cases are expected to resolve within 2-4 weeks.

Last year, the United States had 2 confirmed cases in the US with travelers coming from West Africa.

Identifying the Virus

In a recent statement, CDC said it was tracking clusters of monkeypox in countries that do not normally report monkeypox. Although the agency is not clear how people in those clusters were exposed to the virus, cases have included people who self-identify as men who have sex with men.

The CDC said it is urging US providers to be alert for patients who have rash illnesses consistent with monkeypox, regardless of whether they have traveled or have other specific risk factors for monkeypox.

“Many of these global reports of monkeypox cases are occurring within sexual networks. However, healthcare providers should be alert to any rash that has features typical of monkeypox. We’re asking the public to contact their healthcare provider if they have a new rash and are concerned about monkeypox,” said Inger Damon, MD, PhD, director of CDC’s Division of High-Consequence Pathogens and Pathology, where the agency’s poxvirus research is based.

Vaccine Availability

One vaccine has been approved for prevention of monkeypox. The US does have a stockpile of available monkeypox vaccines. And for those who have had smallpox vaccines these can provide protection against monkeypox as well.


As this is an evolving story, check back on Contagion for news updates.


Related to this article

Ebola and the Ongoing Tale of US Failures
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
Measles Update: September 25, 2026
The latest CDC numbers show a 5.4% increase of measles cases from week-to-week. This year has already become the worst for the number of measles cases in the US since the disease was declared eliminated in 2000. With the start of respiratory virus season, case numbers are expected to continue to increase significantly.
Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.